EU RISK MANAGEMENT PLAN
2 spike protein (produced by recombinant DNA technology using Baculovirus expression system in an insect cell line that is derived from Sf9 cells of the Spodoptera frugiperda) and is adjuvanted with Matrix-M. The adjuvant Matrix-M contains per 0.5 mL: Fraction-A (42.5 µg) and Fraction-C (7.5 µg) of Quillaja saponaria Molina extract.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Product, Management, Lifecycle, Product lifecycle management
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guidelines, Good, Practices, Clinical, Good clinical practice e6
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
Guidelines, European, Agency, Medicine, Harmonised, European medicines agency, Ich harmonised
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Product, Medicinal, Traditional, Herbal, Products1 traditional herbal medicinal products, Products1
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Good, Practices, Pharmaceutical, Manufacturing, Active, Ingredients, Good manufacturing practice for active, Good manufacturing practice for active pharmaceutical ingredients
Related documents
BIOLOGY - cisce.org
cisce.org(Baculovirus), and (v) Microbes as biofertilisers (Rhizobium, Azospirillum, Azotobacter, Mycorrhiza, Cyanobacteria), IPM, harmful effects of chemical pesticides. 4. Biotechnology and itsApplications (i) Biotechnology - Principles and processes. Genetic Engineering (recombinant DNA
Pichia Expression Kit - Thermo Fisher Scientific
tools.thermofisher.comeukaryotic expression systems such as baculovirus or mammalian tissue culture, and generally gives higher expression levels. Yeast shares the advantages of molecular and genetic manipulations with . Saccharomyces, and has the added advantage of 10- to 100-fold higher heterologous protein expression levels. These
FICHA TÉCNICA CERVARIX - Gob
www.gob.mxtecnología de ADN recombinante usando un sistema de expresión de baculovirus 2El sistema adyuvante AS04, patentado por GlaxoSmithKline, está compuesto de hidróxido de aluminio y 3-O-desacil-4’-monofosforil lípido A (MPL) (ver Farmacodinámia). 4. Forma farmacéutica Suspensión inyectable 5. Datos clínicos 5.1. Indicaciones terapéuticas
SIZE 1 - TRP1/QSP1/RDI1 - hubbellcdn
hubbellcdn.comGEOPAK SERIES 1 SIZE 1 - TRP1/QSP1/RDI1 © 2022 Hubbell Outdoor Lighting, a division of Hubbell Lighting, Inc. Specifications subject to change without notice.